MB
BCRX icon

MPM BioImpact’s BioCryst Pharmaceuticals BCRX Stock Holding History

MPM BioImpact’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-605,663
Closed -$7.63M – 36
2022
Q3 		$7.63M Sell
605,663
-33,426
-5% -$430K 1.81% 15
2022
Q2 		$6.76M Hold
639,089
– – 1.88% 13
2022
Q1 		$10.4M Sell
639,089
-22,862
-3% -$367K 2.79% 8
2021
Q4 		$9.17M Sell
661,951
-42,816
-6% -$567K 1.67% 15
2021
Q3 		$10.1M Buy
+704,767
New +$11.1M 1.57% 15

Other funds holding BCRX

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

MPM BioImpact's BCRX Position: Q4 2022 in Review

MPM BioImpact sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 605,663 shares — an estimated $7.63M sold.

MPM BioImpact first reported a position in BCRX in Q3 2021 and held it in 5 quarters. The position peaked at $10.4M in Q1 2022. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

  • MPM BioImpact reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • MPM BioImpact sold 605,663 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $7.63M.
  • MPM BioImpact first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 5 quarters.
  • MPM BioImpact's BioCryst Pharmaceuticals position peaked at $10.4M in Q1 2022.
  • 230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.